Prime Medicine, Inc. (PRME) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $602M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPrime Medicine, Inc. (PRME) trades at $3.33 with MoonshotScore 10/100 (Grade F). Prime Medicine, Inc. is a biotechnology company focused on delivering genetic therapies through gene editing technology.
Price as of Sep 10, 2026 · Last analyzed: Sep 10, 2026Prime Medicine, Inc. is a biotechnology company focused on delivering genetic therapies through gene editing technology. They offer Prime Editors and pegRNAs to target and edit specific genomic locations.
PRME stock analysis for 2026: Analysts have set a consensus price target of $7.50 for Prime Medicine, Inc., suggesting 124.9% upside from the current price of $3.33. The AI MoonshotScore is 10/100, in the Weak band (below 45) — a research signal, not a recommendation. Key factors: analyst coverage, AI-driven quantitative scoring.
PRME: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Strongest side: Momentum (5/10, Neutral). Weakest side: Financial Safety (1/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Prime Medicine, Inc. Company Overview
Research confidence
Broad, current evidence sits behind this analysis.
- ● Scored on 91% of our measures
- ● Price is current
- ● Latest filing 36 days ago
- ● Covered by analysts
Why 10?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.48 Revenue growth (Growth)
- +0.07 3-month price trend (Momentum)
What is holding it back
- -0.78 Gross margin (Business Quality)
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
Risk penalties applied
- -1.89 Bankruptcy-risk score in the distress zone
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
Quarterly Financial Performance: Prime Medicine, Inc.
Revenue for Prime Medicine, Inc. came in at $1.2M during Q2 FY2026, a 34.8% improvement versus the preceding quarter. The company recorded a net loss of $42.1M, with diluted EPS of $-0.24. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap its sector company. Across the four most recent quarters, PRME averaged $-0.28 in diluted EPS.
PRME Valuation & Market Position
With a $602M market cap, Prime Medicine, Inc. sits in the small-cap segment of the market.
PRME Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1M | -$42M | -$0.24 |
| Q1 FY2026 | $856,000 | -$49M | -$0.28 |
| Q4 FY2025 | $838,000 | -$46M | -$0.26 |
| Q3 FY2025 | $1M | -$51M | -$0.32 |
Q2 FY2026 · filed 6 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
PRME Latest News
No recent news available for PRME.
PRME Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PRME.
Price Targets
Consensus target: $7.50
PRME MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. PRME scores 10/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Common Questions About PRME
What does the AI Score mean for PRME?
PRME holds an AI Score of 10/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is PRME a good stock?
Stock Expert AI does not rate PRME buy, sell or hold. Prime Medicine, Inc. carries a MoonshotScore of 10/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key factors to evaluate for PRME?
Prime Medicine, Inc. (PRME) holds an AI score of 10/100 (low). Analysts target $7.50 (+125%). Not financial advice.
How frequently does PRME data refresh on this page?
PRME's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PRME's recent stock price performance?
Prime Medicine, Inc. (PRME) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PRME overvalued or undervalued right now?
Prime Medicine, Inc. (PRME) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Analysts target $7.50 (+125%) — upside seen. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of PRME?
Yes, most major brokerages offer fractional shares of Prime Medicine, Inc. (PRME) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track PRME's earnings and financial reports?
Prime Medicine, Inc. (PRME) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for PRME earnings announcements.
What should investors new to PRME understand first?
Prime Medicine, Inc. (PRME) is worth researching across volatility, fundamentals, and industry context. Its current AI score is 10/100. With a market cap of $602.36M, its size is a factor in volatility characteristics. Start with the Company Overview and MoonshotScore tabs for a structured introduction.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.